An independent review published in JAMA confirms that the flu vaccine continues to lower the risk of severe illness, hospitalisation and death, with no new safety concerns detected for the upcoming 2026-2027 season. The findings support ongoing vaccination efforts amid updated formulations and ongoing debates about vaccine effectiveness.
An independent evidence review published in JAMA on Wednesday says flu vaccination remains linked to a lower risk of severe illness, hospital admission and death, while comparative studies found no new safety concerns for currently recommended immunisations. The review was produced by the Vaccine Integrity Project at the University of Minnesota’s Centre for Infectious Disease Research and Policy, working with the American Medical Association, and was published alongside companion reviews on COVID-19 and RSV vaccines.
The review matters because it fills a procedural gap. The federal advisory committee that usually evaluates the evidence for seasonal respiratory vaccines has not yet issued 2026-2027 recommendations, so the private review was commissioned to help guide medical society advice for the coming season. According to the JAMA summary, the influenza analysis drew on 299 eligible studies, most published between August 2025 and June 2026, and updated rather than replaced the evidence base used for last season’s review.
Its central message is familiar but important: flu shots do not guarantee that someone will avoid infection, but they continue to offer meaningful protection against the worst outcomes. JAMA said the benefit varied by season, age and risk group, which reflects how influenza vaccines are matched months ahead to the strains researchers expect to circulate. In practical terms, that means the value of vaccination is seen most clearly in reduced hospital admissions and fewer deaths, rather than in perfect prevention of every mild case.
The figures in the review underline that point. Evidence cited in the briefing found 31% protection against influenza-associated hospital admission in older adults, based on network surveillance data, and 80% effectiveness against laboratory-confirmed influenza-associated death among children and adolescents across eight flu seasons. The scale of the disease burden remains substantial: respiratory season resources cited by the project, drawing on CDC estimates, say influenza was associated with 390,000 to 800,000 hospitalisations during the 2025-2026 season.
Safety findings were framed carefully. The review did not say flu vaccines are risk-free; rather, comparative studies of current immunisations did not identify any new safety signals. That is a narrower claim, and it sits alongside the well-known short-term side effects of vaccination, such as arm soreness, fatigue and mild fever. The broader point is that an additional year of published research did not uncover a previously unrecognised problem.
The new review also arrives as the 2026-2027 flu shots are already being rolled out. The CDC says vaccines for the season are available for people aged 6 months and older, and that the formulation has been updated to target viruses expected to dominate this winter, including changes to the influenza A(H3N2) subclade K strain that spread widely last season. The American Medical Association said the reviews support use of influenza, COVID-19 and RSV immunisations to reduce severe illness, hospitalisation and death.
For families deciding whether to book an appointment, the practical message is straightforward. The evidence still supports flu vaccination, especially for older adults, young children, pregnant people and those with chronic conditions, who are at greatest risk of serious complications. Coverage may depend on insurance rules, so checking with a plan before heading to a pharmacy or clinic remains sensible, but the scientific case for vaccination has not weakened.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
